SG11201706451TA - 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists - Google Patents
1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonistsInfo
- Publication number
- SG11201706451TA SG11201706451TA SG11201706451TA SG11201706451TA SG11201706451TA SG 11201706451T A SG11201706451T A SG 11201706451TA SG 11201706451T A SG11201706451T A SG 11201706451TA SG 11201706451T A SG11201706451T A SG 11201706451TA SG 11201706451T A SG11201706451T A SG 11201706451TA
- Authority
- SG
- Singapore
- Prior art keywords
- arylsulfonyl
- het
- pyrrolidine
- piperidine
- carboxamide derivatives
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 2
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015073102 | 2015-02-15 | ||
CN2015076318 | 2015-04-10 | ||
CN2016071061 | 2016-01-15 | ||
PCT/EP2016/052950 WO2016128529A1 (en) | 2015-02-15 | 2016-02-12 | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201706451TA true SG11201706451TA (en) | 2017-09-28 |
Family
ID=55349845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706451TA SG11201706451TA (en) | 2015-02-15 | 2016-02-12 | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
Country Status (21)
Country | Link |
---|---|
US (1) | US10179782B2 (en) |
EP (1) | EP3256463B1 (en) |
JP (1) | JP6700291B2 (en) |
KR (1) | KR20170118166A (en) |
CN (1) | CN107922392B (en) |
AU (1) | AU2016217851A1 (en) |
BR (1) | BR112017017052A2 (en) |
CA (1) | CA2975196A1 (en) |
CL (1) | CL2017001987A1 (en) |
CO (1) | CO2017007679A2 (en) |
CR (1) | CR20170367A (en) |
EA (1) | EA033497B1 (en) |
HK (1) | HK1251815A1 (en) |
IL (1) | IL253478A0 (en) |
MX (1) | MX2017010300A (en) |
PE (1) | PE20180177A1 (en) |
PH (1) | PH12017501478A1 (en) |
PT (1) | PT3256463T (en) |
SG (1) | SG11201706451TA (en) |
TW (1) | TW201639829A (en) |
WO (1) | WO2016128529A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201492223A1 (en) | 2012-06-13 | 2015-03-31 | Ф. Хоффманн-Ля Рош Аг | NEW DIAZASPYROCYCLO ALKANES AND AZASPIROCYCLO ALKANES |
EP2900669B1 (en) | 2012-09-25 | 2019-09-04 | F.Hoffmann-La Roche Ag | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
AR095079A1 (en) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO |
KR20160087900A (en) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | New octahydro-cyclobuta [1,2-c ; 3,4-c']dipyrrol-2-yl |
UA119347C2 (en) | 2014-03-26 | 2019-06-10 | Ф. Хоффманн-Ля Рош Аг | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
CN106103446B (en) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | Bicyclic compound as autocrine motility factor (ATX) and lysophosphatidic acid (LPA) production inhibitor |
TWI676626B (en) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | Inhibiting the transient receptor potential a1 ion channel |
SG10201913603QA (en) | 2014-10-06 | 2020-02-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
CA2977947A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
ES2872553T3 (en) | 2015-03-06 | 2021-11-02 | Pharmakea Inc | Lysyl oxidase type-2 inhibitors and uses thereof |
MA41898A (en) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | BICYCLIC QUINAZOLINONE DERIVATIVES |
EP3317258A4 (en) * | 2015-07-01 | 2019-06-26 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
AU2016316717B2 (en) | 2015-09-04 | 2021-02-18 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
KR20180053408A (en) | 2015-09-24 | 2018-05-21 | 에프. 호프만-라 로슈 아게 | A novel biocompatible compound as an autoantix (ATX) / carbonic anhydrase (CA) inhibitor |
WO2017050792A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
EP3353180B1 (en) | 2015-09-24 | 2022-03-16 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
MX2018001430A (en) | 2015-09-24 | 2018-04-20 | Hoffmann La Roche | New bicyclic compounds as dual atx/ca inhibitors. |
CN108602807B (en) | 2016-02-05 | 2022-05-13 | Ea制药株式会社 | Heterocyclic sulfonamide derivatives and drugs containing the same |
JP7043483B2 (en) * | 2016-07-20 | 2022-03-29 | エフ.ホフマン-ラ ロシュ アーゲー | Bicyclic proline compound |
EP3487849A1 (en) | 2016-07-20 | 2019-05-29 | H. Hoffnabb-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
WO2018029288A1 (en) * | 2016-08-12 | 2018-02-15 | F. Hoffmann-La Roche Ag | Sulfonyl pyridyl trp inhibitors |
EP4052707A1 (en) | 2016-09-07 | 2022-09-07 | Pharmakea, Inc. | Uses of a lysyl oxidase-like 2 inhibitor |
BR112019004517A2 (en) | 2016-09-07 | 2019-08-13 | Pharmakea Inc | crystalline forms of a lysyl oxidase-like inhibitor 2 and preparation methods |
US10793547B2 (en) | 2016-12-09 | 2020-10-06 | Vertex Pharmaceuticals Incorporated | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP3554500A1 (en) | 2016-12-16 | 2019-10-23 | Galderma Research & Development | Trpa1 antagonists for use in the treatment of atopic dermatitis |
KR102515694B1 (en) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | Heterocycle derivatives as pest control agents |
RU2019132254A (en) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | HETEROCYCLIC COMPOUNDS SUITABLE AS DUAL ATX / CA INHIBITORS |
CN110382484B (en) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | Novel bicyclic compounds as ATX inhibitors |
AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CN111051280B (en) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | Process for preparing pyrrolidine compounds |
CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
JP7245834B2 (en) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | A process for creating modulators of cystic fibrosis transmembrane conductance regulators |
TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
WO2019164778A1 (en) | 2018-02-20 | 2019-08-29 | Genentech, Inc. | Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US12043615B2 (en) | 2018-12-07 | 2024-07-23 | Unimatec Co., Ltd. | Fluorine-containing pyrimidine compound and method for manufacturing the same |
CN110156834A (en) * | 2019-06-05 | 2019-08-23 | 镇江市高等专科学校 | A kind of yellow fluorescence copper (I) complex and its preparation method and application |
FR3114235A1 (en) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | INHIBITION OF ASTROCYTIC TRPA1 CHANNEL AS A NEW NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE |
CA3198930A1 (en) * | 2020-11-19 | 2022-05-27 | Acousia Therapeutics Gmbh | Non-aqueous gel composition |
IT202100015098A1 (en) | 2021-06-09 | 2022-12-09 | Flonext S R L | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE DISEASES OF THE RETINA |
WO2023133502A1 (en) * | 2022-01-07 | 2023-07-13 | The Johns Hopkins University | Treatment and prevention of trigeminal neuralgia |
WO2024146945A1 (en) | 2023-01-07 | 2024-07-11 | Syngenta Crop Protection Ag | Novel carboxamide and sulfonamide pesticidal compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614201B2 (en) * | 2009-06-05 | 2013-12-24 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of TRPA1 |
EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
WO2013108857A1 (en) * | 2012-01-17 | 2013-07-25 | 味の素株式会社 | Heterocyclic amide derivative and pharmaceutical product containing same |
EP2937335A4 (en) | 2012-12-18 | 2016-09-14 | Ea Pharma Co Ltd | Heterocyclic amide derivative, and medicine containing same |
TW201441225A (en) * | 2013-01-18 | 2014-11-01 | Cubist Pharm Inc | Inhibiting the transient receptor potential A1 ion channel |
US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
LT3055302T (en) | 2013-10-11 | 2019-03-12 | F. Hoffmann-La Roche Ag | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
RU2016134749A (en) | 2014-01-28 | 2018-03-02 | ЕА Фарма Ко., Лтд. | HETEROCYCLIC SULPHONAMIDE DERIVATIVE AND MEDICINE CONTAINING SUCH DERIVATIVE |
-
2016
- 2016-02-12 JP JP2017542390A patent/JP6700291B2/en active Active
- 2016-02-12 SG SG11201706451TA patent/SG11201706451TA/en unknown
- 2016-02-12 US US15/042,310 patent/US10179782B2/en active Active
- 2016-02-12 CA CA2975196A patent/CA2975196A1/en not_active Abandoned
- 2016-02-12 WO PCT/EP2016/052950 patent/WO2016128529A1/en active Application Filing
- 2016-02-12 MX MX2017010300A patent/MX2017010300A/en unknown
- 2016-02-12 PE PE2017001378A patent/PE20180177A1/en unknown
- 2016-02-12 PT PT167039908T patent/PT3256463T/en unknown
- 2016-02-12 AU AU2016217851A patent/AU2016217851A1/en not_active Abandoned
- 2016-02-12 BR BR112017017052-3A patent/BR112017017052A2/en not_active IP Right Cessation
- 2016-02-12 EA EA201791836A patent/EA033497B1/en not_active IP Right Cessation
- 2016-02-12 CR CR20170367A patent/CR20170367A/en unknown
- 2016-02-12 KR KR1020177025946A patent/KR20170118166A/en unknown
- 2016-02-12 EP EP16703990.8A patent/EP3256463B1/en active Active
- 2016-02-12 CN CN201680009724.XA patent/CN107922392B/en active Active
- 2016-02-15 TW TW105104384A patent/TW201639829A/en unknown
-
2017
- 2017-07-13 IL IL253478A patent/IL253478A0/en unknown
- 2017-07-28 CO CONC2017/0007679A patent/CO2017007679A2/en unknown
- 2017-08-03 CL CL2017001987A patent/CL2017001987A1/en unknown
- 2017-08-15 PH PH12017501478A patent/PH12017501478A1/en unknown
-
2018
- 2018-08-31 HK HK18111222.7A patent/HK1251815A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CO2017007679A2 (en) | 2017-10-20 |
EA033497B1 (en) | 2019-10-31 |
CA2975196A1 (en) | 2016-08-18 |
WO2016128529A1 (en) | 2016-08-18 |
MX2017010300A (en) | 2017-12-04 |
US20160264567A1 (en) | 2016-09-15 |
JP6700291B2 (en) | 2020-05-27 |
TW201639829A (en) | 2016-11-16 |
PT3256463T (en) | 2019-12-05 |
PE20180177A1 (en) | 2018-01-22 |
CL2017001987A1 (en) | 2018-08-24 |
EA201791836A1 (en) | 2017-12-29 |
JP2018513107A (en) | 2018-05-24 |
CR20170367A (en) | 2017-09-12 |
US10179782B2 (en) | 2019-01-15 |
AU2016217851A1 (en) | 2017-08-03 |
IL253478A0 (en) | 2017-09-28 |
KR20170118166A (en) | 2017-10-24 |
CN107922392B (en) | 2020-07-21 |
CN107922392A (en) | 2018-04-17 |
HK1251815A1 (en) | 2019-03-29 |
PH12017501478A1 (en) | 2018-01-29 |
EP3256463A1 (en) | 2017-12-20 |
BR112017017052A2 (en) | 2018-04-10 |
EP3256463B1 (en) | 2019-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251815A1 (en) | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists | |
ZA201805544B (en) | Substituted piperidine compound and use thereof | |
HK1255102A1 (en) | Heterocyclic compounds and uses thereof | |
HK1245244A1 (en) | Heterocyclic amides as kinase inhibitors | |
IL266472A (en) | Indazole derivatives as v integrin antagonists | |
HK1251902A1 (en) | Bridged piperidine derivatives | |
IL252560A0 (en) | Heterocyclic derivatives and use thereof | |
ZA201606141B (en) | Piperidine derivatives as orexin receptor antagonist | |
EP3724194C0 (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
PL3245198T3 (en) | Pyrrolidine derivatives as angiotensin ii type 2 antagonists | |
FI3724196T3 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
PL3268356T3 (en) | Heterocyclic compounds and methods for their use | |
IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
ZA201704949B (en) | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists | |
AU2015903010A0 (en) | Heterocyclic Compounds and Methods for their Use | |
AU2015902922A0 (en) | Heterocyclic compounds and methods for their use | |
AU2015902886A0 (en) | Heterocyclic Compounds And Methods For Their Use | |
AU2015902830A0 (en) | Heterocyclic compounds and methods for their use | |
AU2015901751A0 (en) | Heterocyclic Compounds And Methods For Their Use | |
AU2015900878A0 (en) | Heterocyclic compounds and methods for their use | |
AU2015900077A0 (en) | Heterocyclic compounds and methods for their use |